These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37014400)

  • 1. Critical analysis of the prescription and evaluation of protein kinase inhibitors for oncology in Germany.
    Obst CS; Seifert R
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Oct; 396(10):2529-2543. PubMed ID: 37014400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
    Yıldız M; Osman E
    Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe.
    Vokinger KN; Hwang TJ; Daniore P; Lee CC; Tibau A; Grischott T; Rosemann TJ; Kesselheim AS
    JAMA Oncol; 2021 Sep; 7(9):e212026. PubMed ID: 34196656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Economic aspects in the care of patients with new oral anticancer drugs: findings from the AMBORA trial].
    Dürr P; Schlichtig K; Krebs S; Schramm A; Schötz L; Fromm MF; Dörje F
    Z Evid Fortbild Qual Gesundhwes; 2022 Apr; 169():84-93. PubMed ID: 35249863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The new German drug market law AMNOG from a child and adolescent psychiatry perspective].
    Dittmann RW
    Nervenarzt; 2016 Apr; 87(4):367-75. PubMed ID: 26992908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methods for the comparative evaluation of pharmaceuticals.
    Zentner A; Velasco-Garrido M; Busse R
    GMS Health Technol Assess; 2005 Nov; 1():Doc09. PubMed ID: 21289930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drug assessment: IQWiG, G-BA, and an international comparison].
    Glaeske G
    Internist (Berl); 2016 Jan; 57(1):94-101. PubMed ID: 26502888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health Technology Assessment-Informed Decision Making by the Federal Joint Committee/Institute for Quality and Efficiency in Health Care in Germany and the National Institute for Health and Care Excellence in England: The Role of Budget Impact.
    Schaefer R; Hernández D; Bärnighausen T; Kolominsky-Rabas P; Schlander M
    Value Health; 2023 Jul; 26(7):1032-1044. PubMed ID: 36921901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lessons From The Impact Of Price Regulation On The Pricing Of Anticancer Drugs In Germany.
    Lauenroth VD; Kesselheim AS; Sarpatwari A; Stern AD
    Health Aff (Millwood); 2020 Jul; 39(7):1185-1193. PubMed ID: 32634355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?
    Büssgen M; Stargardt T
    Appl Health Econ Health Policy; 2023 Sep; 21(5):751-759. PubMed ID: 37249741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Actual medical care situation and therapeutic needs in multiple sclerosis: Impact of the Pharmaceutical Market Restructuring Act (AMNOG)].
    Bittner S; Meuth SG
    Nervenarzt; 2016 Apr; 87(4):394-401. PubMed ID: 27023842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Time-Trend Economic Analysis of Cancer Drug Trials.
    Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
    Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early benefit assessment of new drugs in Germany - results from 2011 to 2012.
    Hörn H; Nink K; McGauran N; Wieseler B
    Health Policy; 2014 Jun; 116(2-3):147-53. PubMed ID: 24472328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in Prices of Popular Brand-Name Prescription Drugs in the United States.
    Wineinger NE; Zhang Y; Topol EJ
    JAMA Netw Open; 2019 May; 2(5):e194791. PubMed ID: 31150077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis.
    Vokinger KN; Hwang TJ; Grischott T; Reichert S; Tibau A; Rosemann T; Kesselheim AS
    Lancet Oncol; 2020 May; 21(5):664-670. PubMed ID: 32359489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Crossover in Oncology Clinical Trials on Evidence Levels in Early Benefit Assessment in Germany.
    Isbary G; Staab TR; Amelung VE; Dintsios CM; Iking-Konert C; Nesurini SM; Walter M; Ruof J
    Value Health; 2018 Jun; 21(6):698-706. PubMed ID: 29909875
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.